Exelixis
EXEL
#1620
Rank
โ‚น876.88 B
Marketcap
โ‚น3,133
Share price
-0.38%
Change (1 day)
58.68%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Earnings for Exelixis (EXEL)

Earnings in 2024 (TTM): โ‚น57.32 Billion

According to Exelixis's latest financial reports the company's current earnings are โ‚น2.16 Billion. , an increase over its 2023 earnings that were of โ‚น21.98 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Exelixis from 2000 to 2024

Annual earnings

Year Earnings Change
2024 โ‚น58.19 B164.69%
2023 โ‚น21.98 B9.89%
2022 โ‚น20.00 B-20.33%
2021 โ‚น25.11 B124.82%
2020 โ‚น11.16 B-67.14%
2019 โ‚น33.98 B-11.94%
2018 โ‚น38.59 B185.09%
2017 โ‚น13.53 B-325.82%
2016 -โ‚น6 Billion-58.12%
2015 -โ‚น14.32 Billion-37.61%
2014 -โ‚น22.95 Billion9.75%
2013 -โ‚น20.91 Billion65.96%
2012 -โ‚น12.6 Billion-291.63%
2011 โ‚น6.57 B-195.59%
2010 -โ‚น6.88 Billion-42.17%
2009 -โ‚น11.9 Billion-18.98%
2008 -โ‚น14.68 Billion-6.99%
2007 -โ‚น15.78 Billion46.3%
2006 -โ‚น10.79 Billion33.25%
2005 -โ‚น8.1 Billion-30.92%
2004 -โ‚น11.72 Billion44.29%
2003 -โ‚น8.13 Billion12.86%
2002 -โ‚น7.2 Billion22.79%
2001 -โ‚น5.86 Billion60.14%
2000 -โ‚น3.66 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
โ‚น375.16 B 544.70%๐Ÿ‡ฌ๐Ÿ‡ง UK
โ‚น678.01 B 1,065.14%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚น1.810 T 3,011.17%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น715.32 Billion-1,329.24%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น393.47 B 576.16%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น1.489 T 2,458.83%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น948.71 B 1,530.33%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น3.83 Billion-106.57%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น2.48 Billion-104.26%๐Ÿ‡บ๐Ÿ‡ธ USA